Interleukin-22 (IL-22) is a potential therapeutic agent for diseases driven by epithelial injury. To characterize the IL-22 expressed by rhesus macaques, animals that are irreplaceable for human disease research, rhesus macaque IL-22 (rhIL-22) was cloned and expressed, and its biological activity and in vivo distribution were examined. It was found that the rhIL-22 gene consists of five introns and six exons, including a short noncoding exon starting 22 bp downstream of a putative TATA box. The amino acid sequence of rhIL-22 showed 95Á5% identity to that of humans, and it shared two conserved disulphide bonds, three N-glycosylation sites and all the critical residues for binding to IL-22R1. High levels of IL-22 mRNA were observed in the liver, pancreas, lymphoid tissues and especially in the outer-body barriers such as the intestinal tract of rhesus macaques. Functionally, purified rhIL-22 has a similar but a little earlier effect on signal transducer and activator of transcription 3 phosphorylation at Tyr705 compared with that of commercial human IL-22. The expression of the antibacterial proteins b-defensin-2, S100A8, S100A9, RegIIIa and Muc1 by HT-29 cells was largely upregulated after stimulation with rhIL-22. Recombinant rhIL-22 could also significantly promote the proliferation of human intestinal epithelial cells without affecting cell apoptosis. These data indicate that rhesus macaque IL-22 is highly similar to that of humans in both structure and function, and tests of therapeutic effects of human IL-22 on human diseases in rhesus macaques are warranted.
Introduction
Interleukin-22 (IL-22) was first cloned from a stimulated murine thymus T-cell line in 2000 and identified as a novel member of the IL-10 family, which included IL-10, IL-19, IL-20, IL-24 and IL-26.
1,2 The mature protein of human IL-22 is 146 amino acids in length and shares 79% homology with IL-10. 3 Like other members of the IL-10 family, IL-22 has a bundle-like structure that is composed of a-helices and connecting loops. A broad range of T cells and innate immune cells can produce IL-
22, including CD4
+ T helper type 1 (Th1) cells, Th17 cells, Th22 cells, CD8 + T cells, natural killer cells, T-cell receptor-cd T cells, lymphoid tissue inducer cells and group 3 innate lymphoid cells (ILC3s). 4, 5 Under normal circumstances, the major cellular source of IL-22 seems to vary in different tissues. In skin, the primary IL-22-producing cells are Th22, whereas in lung they are cd T cells and Th17 cells, and in small intestine they are CD4 + T cells and ILC3s. [6] [7] [8] [9] The role of IL-22 is mediated through binding to heterodimeric receptors that comprise IL-22 receptor 1 (IL- 
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22R1) and IL-10R2. As IL-10R2 is ubiquitously expressed, IL-22R1 determines the cellular sensitivity towards IL-22 due to its restricted expression on non-immune cells, including respiratory epithelial cells, intestinal epithelial cells and keratinocytes. 10 This targeted expression leads to the belief that IL-22 may mediate cross-talk between immune cells and epithelial cells in mucosal tissues. Signal transducer and activator of transcription 3 (STAT3) has been documented as the principal transcription factor to mediate a variety of functions of IL-22. Antibacterial proteins such as S100A7, S100A8, S100A9, b-defensin-2 and RegIIIa induced by IL-22 play essential roles against bacterial infection.
11 -13 Interleukin-22 can also promote cell proliferation through up-regulation of the pro-survival proteins Bcl-2 and Bcl-xl, and proliferative factor cyclin D in a STAT3-dependent manner.
14 Additionally, IL-22 is involved in pathological inflammation through regulating the expression of inflammatory cytokines (IL-6, IL-8, IL-11 and leukaemia inhibitory factor), chemokines and matrix metalloproteinases in inflammatory bowel disease. 15 Knowledge of several gut-associated diseases such as Crohn's disease, ulcerative colitis and chronic human immunodeficiency virus infection has indicated that the expression of IL-22 was significantly altered and resulted in dysfunction of antimicrobial defence and tissue regeneration. [16] [17] [18] Owing to the restricted target range of IL-22, especially its lack of influence on immune cells, as well as the functions of regulating mucosal immunity, inflammation and tissue repair, various pre-clinical studies have focused on the therapeutic potential of IL-22 in intestinal epithelial damage and have mostly used mouse models. 19, 20 Protection from severe infection by Citrobacter rodentium and dextran sodium sulphate-induced colitis was observed by injecting recombinant IL-22 or delivering IL-22-expressing plasmid into mice. [21] [22] [23] However, the amino acid sequence of mouse IL-22 shows only 78Á2% similarity to that of humans. Moreover, different sequence characteristics exist between different mouse stains. A single copy of the IL-22 gene was found in BALB/c and DBA/2 mice, whereas duplicate copies were found in C57BL/6, FVB and 129 mice. In addition, amino acid polymorphisms were also found among those mouse strains mentioned above. 24 These differences could complicate the translation of the knowledge obtained in mice to human diseases.
Rhesus macaques are irreplaceable in establishing animal models for human diseases and drug development. There are a few studies using rhesus macaque models that have shown the involvement of IL-22-expressing cells in coeliac disease and simian immunodeficiency virus infection. [25] [26] [27] However, no study on the molecular characteristics of rhesus macaque IL-22 could be found in the literature. To elucidate the molecular property of rhesus macaque IL-22, we cloned the full-length cDNA of rhesus macaque IL-22 by RT-PCR and rapid amplification of cDNA ends (RACE), and examined the abundance and distribution of IL-22 mRNA in various tissues of normal rhesus macaques. Functional comparisons between the effects of purified rhIL-22 and commercial human IL-22 on downstream STAT3 phosphorylation, antibacterial protein expression and cell proliferation were carried out with intestinal epithelial cells (IECs) in vitro.
Materials and methods

Isolation of RNA
The total RNA for cDNA clones was purified from peripheral blood mononuclear cells (PBMCs) of normal Chinese rhesus macaque, which was pre-incubated with 50 ng/ml phytohaemagglutinin (PHA) for 6 hr. The total RNA for real-time RT-PCR was extracted from the thymus, spleen, inguinal lymph node, tonsil, skin, trachea, lung, heart, liver, kidney, pancreas, vagina, oral cavity, proximal duodenum, proximal jejunum, distal ileum, caecum, proximal colon, and rectum of Chinese rhesus macaques. Total RNA from 10-20 mg of each type of tissues or 10 7 PBMCs was extracted with RNAPrep Pure Tissue Kit (Tiangen, Beijing, China) as described previously. 28 Extracted RNA was eluted with 100 ll RNaseFree water and divided into small aliquots and stored at À80°.
Cloning of IL-22 cDNA
Complementary DNA (cDNA) was synthesized from the total RNA of pre-stimulated PBMCs using a SuperScript â III First-Strand Synthesis System (Invitrogen, Carlsbad, CA) following the manufacturer's protocol. The obtained cDNA was then used as the template for PCR with the primer set open-reading frame (ORF) -22F/ ORF-22R. The PCR products were electrophoresed on a 1% agarose gel, and fragments of the expected size were purified with the QIAquick â Gel Extraction Kit (Qiagen, Hilden, Germany) and subsequently cloned into the pGEMT-Easy vector (Promega, Madison, WI). The positive clones were selected and sequenced by the Sangon Biotech Company (Shanghai, China). According to the obtained coding DNA sequence of IL-22, the gene-specific primers for 5 0 -RACE and 3 0 -RACE were designed as shown in Table 1 . The 5 0 -RACE-ready cDNA were synthesized from the total RNA of pre-stimulated PBMCs using a 5 0 -Full RACE Kit with TAP (TaKaRa, Shiga, Japan) as described previously. 29 The 3 0 -RACEready cDNA was reverse transcribed with a designed 3 0 -adaptor as previously described. 30 Then, nested PCR was performed to clone 5 0 -end or 3 0 -end of IL-22 mRNA with the gene-specific primers. The PCR cycling parameters were as follows: an initial denaturation at 94°for ª 2018 John Wiley & Sons Ltd, Immunology, 154, 651-662 2 min, followed by 30 cycles at 94°for 30 seconds, 55°f or 30 seconds, and 72°for 1 min, and the last cycle was followed by 10 min extension at 72°. Additionally, the nested PCR programme was 94°for 2 min; 94°for 30 seconds, 55°for 30 seconds, 72°for 1 min for 30 cycles; and 72°for 10 min. The PCR products were cloned into the pGEMT-Easy vector and subsequently sequenced.
To illustrate the probable promoter and transcription factor binding sites of the IL-22 gene, the cDNA sequence was mapped to the reverse strand of chromosome 11. The nucleotide sequence from À1000 to +160 of the transcription start site was predicted with the JASPAR program.
Construction of expression vector and induced expression of IL-22
The fragment of IL-22 without the predicted signal peptide was amplified from the obtained plasmid containing the IL-22 ORF sequence. The PCR products were double digested with BamHI and XhoI, and inserted into pET28a-sumo plasmid. Then, the recombinant plasmid was transformed into the cells of Escherichia coli strain BL21(DE3). Cultures were grown in LB medium containing 50 µg/ml kanamycin to an optical density at 600 nm (OD 600 ) of 0Á6 at 37°. IPTG was added to the culture to a final concentration of 1 mM for 7 hr at 37°to induce the expression of recombinant IL-22. Cells were harvested by centrifugation for 20 min at 5460 g before proceeding to further purification.
Protein expression and purification
The cell pellets were resuspended in 50 ml bacterial disruption buffer (300 mM NaCl, 0Á5% Triton X-100, 50 mM Tris-HCl pH 8Á0) and subjected to sonication at 300 W for 40 min (5 seconds working, 9 seconds free) on ice. The inclusion bodies were collected by centrifugation and washed extensively with washing 
The probes were modified with FAM at the 5 0 end and TAMRA at the 3 0 end. buffer (2 M urea, 300 mM NaCl, 1 mM EDTA, 0Á5% Triton-X-100, 5 mM b-mercaptoethanol and 50 mM TrisHCl, pH 8Á0). After the inclusion bodies were dissolved in denaturing buffer (8 M urea, 300 mM NaCl, 50 mM Tris-HCl, pH 8Á0), the solubilized recombinant IL-22 was refolded by infinite dilution in refolding buffer (150 mM NaCl, 0Á4 M L-arginine, 5 mM reduced glutathione, 0Á5 mM oxidized glutathione and 50 mM Tris-HCl, pH 8Á0) and incubated at 4°overnight while stirring. After incubation, the folded mixture was then concentrated by ultrafiltration in an Amicon chamber with a YM10 membrane before protein cleavage. Sumo protease (Smart-Lifesciences, Changzhou, China) was added to the protein solution to cleave off the His-SUMO fusion from recombinant IL-22. The cleavage reaction was incubated at 4°overnight while stirring. An Ni-NTA column, preequilibrated with binding buffer (150 mM NaCl and 50 mM Tris-HCl, pH 8Á0), was loaded with approximately 10 ml of cleaved mixture. The protein was eluted with elution buffer (50 mM Tris-HCl, 150 mM NaCl, 50 mM imidazole, pH 8Á0) and subsequent to dialysis several times in a buffer containing 50 mM Tris-HCl, 150 mM NaCl, pH 8Á0) to remove the imidazole.
Quantitative real-time PCR
Relative real-time RT-PCR for analysing the altered expression of Bcl-2, Mcl-1, Bcl-xL, BD-2, S100A8, S100A9, RegIIIa and Muc1 was performed using SYBR Green PCR Master Mix (TaKaRa) according to the manufacturer's protocol, and gene expression was expressed as DCT normalized to the CT levels of GAPDH. An absolute quantification method based on a standard curve for analysing the mRNA abundance and distribution of rhIL-22 was established, and quantitative RT-PCR was performed with specific Taqman probes by using the One step real-time RT-PCR kit (TaKaRa). Data were expressed as the number of copies calculated according to the standard curve and normalized to GAPDH.
Western blot
We loaded 30 µl of supernatant or cell lysate with 59 loading buffer onto 12% SDS-PAGE. Proteins were transferred to PVDF membranes (Millipore, Darmstadt, Germany), blocked, incubated overnight with anti-His (ZSGB-BIO, Beijing, China), anti-pSTAT3 (Ser727) and anti-STAT3
(Santa Cruz Technology, Dallas, TX), and anti-pSTAT3 (Tyr705; WanleiBio, Shenyang, China) primary antibodies, and then incubated with secondary antibody horseradish peroxidase-anti-mouse IgG (ZSGB-BIO) at 37°for 1 hr. The SuperSignal TM West Dura substrate (Thermo, Waltham, MA) was used to detect protein bands.
Cell proliferation and apoptosis assay
HT-29 cells were seeded into 96-well plates at a density of 2000 cells per well and allowed to attach for 12 hr. Cells were consistently treated with cytokine-free medium for further cultivation overnight. We added 100 ng/ml of purified rhIL-22 or huIL-22 to each well for continued cultivation. Twenty microlitres (5 mg/ml) of MTT solution was added to each well and incubated for 4 hr at 37°. The medium was removed, and 150 ll dimethyl sulphoxide was added to dissolve the violet crystals. The absorbance was measured at 570 nm with a microplate reader (BioTek, Winooski, VT). Furthermore, HT-29 cells were prestained with 2 nM carboxyfluorescein diacetate succinimidyl ester (CFSE) and seeded into 24-well plates at a density of 5 9 10 4 overnight. Cells were harvested each day with 0Á25% trypsin and prepared as single-cell suspensions. Cells were acquired using FASCalibur (BD, Franklin Lakes, NJ) and data were analysed with FLOWJO 7.6 software (Tree Star Inc., Ashland, OR). The effects of rhIL-22 on serum starvation-induced apoptosis of HT-29 cells were examined with propidium iodide as described previously, 31 and mRNA levels of anti-apoptosis genes were examined with real-time RT-PCR.
Data analysis
All values of real-time RT-PCR tests were expressed as mean AE SD, and the mRNA levels were corrected with GAPDH mRNA levels. Statistical comparisons of the results were performed using Student's two-tailed t-test, and P-values < 0Á05 were considered significant.
Results
Nucleotide sequence of rhesus macaque rhIL-22 cDNA First, the nucleotide sequence of rhIL-22 ORF was cloned from the PHA-stimulated PBMC total RNA by using RT- PCR. A band migrating at approximately 540 bp was detected. After sequencing and alignment, it was found that the sequence obtained by cloning is exactly the same as the predicted sequence of rhIL-22 in GenBank (accession no. NM_001194724.1), which confirmed that the cDNA-encoding IL-22 had been isolated from rhesus macaque.
The sequence and organization of the rhIL-22 gene was then identified by using RACE PCR and further genome mapping. As shown in Fig. 1(a) , rhIL-22 gene is located on the reverse strand of chromosome 11 and contains six exons spanning approximately 6 kb, and the complete sequence of exon1 is located in the 5 0 untranslated region (UTR). The cDNA of rhIL-22 is 1163 bp in length, and it contains a 69 bp 5 0 -UTR, a 540 bp ORF, and a 494 bp 3 0 -UTR with a single typical polyadenylation signal (AATAAA) at position 1128, just 14 bp upstream of poly (A) tail. Additionally, the 3 0 -UTR contains six mRNA instability motifs (ATTTA) (Fig. 1b) .
The results of probable promoter and transcription factor binding sites analysis are shown in Fig. 1(c) . Although there were two TATA-box candidates located À382 bp and À22 bp upstream of the transcription start site, the second TATA box initiated the mRNA transcription due to the presence of CCAAT-enhancerbinding proteins b and transcription factor II D upstream. Multiple conserved transcription factor binding sites within the 500 bp region upstream of transcription start site were identified using JASPAR program.
The possible binding elements including those for interferon regulatory factor 2, transcription factor forkhead box P3, C2H2 zinc finger factor YY1, NFAT-related factors (NF-AT1 and NF-AT2), and GATA binding factors 1 and 3 were also predicted.
Phylogenetic relationships of IL-22
The isolated cDNA of rhIL-22 encodes a protein of 179 amino acids, the first 33 of which were predicted to function as a signal sequence. Multiple alignment of the protein sequence indicated that rhIL-22 has much higher homology with human (95Á5%) than with mouse (79%) or rat (76Á5%). According to previous functional studies, the AB loop and helix F, which were the main receptor binding domains of IL-22 were conserved among those sequences. Additionally, the critical residues for receptor binding activity coincided with that of human IL-22 as well (Fig. 2a) . The phylogenetic tree shown in Fig. 2 (b) was constructed according to the amino acid sequences without signal peptide of rhIL-22 and other IL-22 from different species. The tree revealed that rhIL-22 exhibited the highest homology with human IL-22 among different animal models. All of the IL-22 sequences selected from 
Distribution of IL-22 in rhesus macaques
To detect the abundance of IL-22 mRNA in various tissues, a real-time RT-PCR method was established, and the total RNA samples of the thymus, spleen, inguinal lymph node, tonsil, skin, trachea, lung, heart, liver, kidney, pancreas, vagina, oral cavity, proximal duodenum, proximal jejunum, distal Ileum, caecum, proximal colon and rectum were examined. As shown in Fig. 3 , the value of spleen was the highest, whereas rhIL-22 mRNA could hardly be detected in heart, kidney and oral cavity. The expression of IL-22 mRNA in organs such as the liver, pancreas and tonsil could also be detected. Interestingly, all the barrier surface tissues such as the skin, respiratory tract, vagina and especially the intestinal tract of rhesus macaques had relatively high expression levels of IL-22 mRNA, which suggests that rhIL-22 has a potentially important role in the mucosa.
In vitro expression of rhIL-22
Recombinant expression plasmid was verified by double digestion with BamHI and Xhol after subcloning into the pET28-sumo vector (Fig. 4a) . A band of approximately 45 000 MW in the insoluble fraction was observed on SDS-PAGE for the induced bacterial sample and purified fusion protein. However, this band was not observed in the cases of either non-induced recombinant bacteria, or induced bacteria transformed with the empty pET28a-sumo plasmid (Fig. 4b) . After isolation and purification from the inclusion bodies as described above, mature rhIL-22 was produced by proteolysis of the recombinant fusion protein with sumo protease. The rhIL-22 products were separated from His-sumo by Ni-NTA affinity column. As represented in Fig. 4(c) , apart from a small amount of rhIL-22 in the flow through, the separation efficiency was the highest using imidazole at a final concentration of 50 mM. As shown in Fig. 4(d) , a specific band obtained by Western blot assay demonstrated that rhIL-22 recombinant protein was successfully expressed.
Recombinant rhIL-22 induced STAT3 phosphorylation and antibacterial protein expression
To determine the biological activity of the obtained rhIL-22 described above and compare its ability to induce STAT3 phosphorylation with that of huIL-22, we treated HT-29 cells with 100 ng/ml of rhIL-22 or huIL-22 for 15, 30 and 60 min. Western blot analysis showed that 15 min of huIL-22 stimulation led to clear tyrosine phosphorylation of STAT3, this reaction was even stronger at 30 min and decreased with time until 60 min after stimulation.
Whereas rhIL-22 induced a higher level of phosphorylation at 15 min and maintained until 60 min, when it began to decrease. Interestingly, compared with the tyrosine phosphorylation of STAT3, serine phosphorylation of STAT3 was not observed with either rhIL-22 or huIL-22 stimulation (Fig. 5a ). At the same time, downstream antibacterial proteins such as b-defensin-2, S100A8, S100A9, RegIIIa and Muc1 were assessed by real-time RT-PCR to evaluate the antibacterial activity of rhIL-22. As represented in Fig. 5(b) , all of the antibacterial proteins were increased to different degrees in the presence of rhIL-22 and huIL-22. Among those downstream genes, the expression of S100A8 and S100A9 were moderately up-regulated (2Á8-fold and 1Á8-fold), whereas Muc1 and RegIIIa expression were significantly increased (11Á9-fold and 7Á8-fold). There were no significant difference between rhIL-22 and huIL-22 in inducing the expression of antimicrobial proteins including BD-2, S100A8, Muc1 and RegIIIa by HT-29 cells (P = 0Á6876, P = 0Á8587, P = 0Á3206 and P = 0Á7692, respectively). However, the expression level of S100A9 induced by huIL-22 was slightly higher than that of rhIL-22 (P = 0Á0141).
Recombinant rhIL-22 promoted HT-29 cell proliferation
To explore the role of proliferation acting on IECs, we stimulated HT-29 cells with different concentrations of rhIL-22 (0, 50, 100 and 400 ng/ml), and examined cell proliferation with MTT kits. It was found that rhIL-22 can significantly induce cell proliferation at 50 ng/ml, and enhanced effects were observed at 100 ng/ml, whereas there was a trend for an antiproliferative effect at 400 ng/ml of rhIL-22 (Fig. 6a) . To further compare its proliferative ability with that of commercially available huIL-22, 100 ng/ml was selected to stimulate the cells and examined cell proliferation with an MTT kit. The results showed that the activity of purified rhIL-22 was comparable to that of huIL-22, and the proliferative curves were almost the same (Fig. 6b) . Simultaneously, Celltrace CFSE cell proliferation kits (ThermoFisher, Waltham, MA) were also used to trace cell proliferation at a series of time-points. It was found intuitively from the histogram that both rhIL-22 and huIL-22 could enhance the proliferation of HT-29 cells to a similar degree when compared with the untreated group and CFSE-stained day 0 samples (Fig. 6c) . The effects of rhIL-22 on serum starvation-induced apoptosis of HT-29 cells were also examined. As shown in Fig. 7 (a), after 3 days of serum starvation, 14Á01% cells were undergoing apoptosis (sub-G1 phase). Similarly, cells treated with huIL-22 or rhIL-22 possessed 14Á36% and 18Á05% apoptosis cells, respectively. In addition, several anti-apoptosis genes, including Bcl-xL, Bcl-2 and Mcl-1 showed no significant difference between the rhIL-22-treated group and serum-deprived group (Fig. 7b ).
Discussion
Interleukin-22 is an important member of the IL-10 family, which also contains IL-10, IL-19, IL-20, IL-24 and IL-26. 2 In this study, we cloned the full-length cDNA of IL-22 from rhesus macaques and analysed its molecular characteristics. The cDNA of rhIL-22 contained one more exon in the 5 0 -UTR but with fewer ATTTA motifs in the 3 0 -UTR, which might be involved in regulating the stability of the mRNA. However, several similarities of other molecular characteristics between rhesus macaques and humans suggested that they may have the same functions. First, the rhIL-22 gene is located on the reverse strand of rhesus macaque chromosome 11, adjacent to IFN-c and IL-26, which is similar to human IL-22. This IFN/IL-10-related cytokine cluster may indicate that IL-22 is involved in immune and inflammation responses, which is also corresponding to recent studies confirming that huIL-22 plays dual roles in inflammatory responses. 6 Second, the presence of a number of putative transcription factor binding sites that regulate the expression and function of human IL-22 has been confirmed in accumulating studies. NF-AT2 and CREB were demonstrated to contribute to rapid IL-22 gene induction under the influence of T/A. 32 The presence of two GATA family members (GATA-1 and GATA-3) was predicted as well. It has been demonstrated that GATA-3 was critical for the homeostasis of ILC3s, the development of NKp46 + ILC3s and IL-22 production by ILC3s. 33 Last, rhIL-22 showed 95Á5% amino acid sequence identity to that of human IL-22 and contained the conserved cysteine residues, N-glycosylation sites and even critical residues for receptor binding. However, the amino acid sequence of mouse IL-22 showed only 78Á2% homology with that of humans, not to mention the considerable difference in their receptors IL-22R1 (71Á9%). Hence, rhIL-22 can be used as an excellent substitution for human IL-22 in gene expression regulation researches.
Furthermore, several bioactivities of purified rhIL-22 acting on a human intestinal cell line (HT-29) were consistent with that of human IL-22, which highlights the excellent substitution of rhIL-22 in studies of IL-22-associated mucosal immunity. First, rhIL-22 mediated the phosphorylation of STAT3 at the Tyr705 residue, which is the dominant response molecule in the signal transduction of human IL-22. 20 Second, rhIL-22 can significantly up-regulate the expression of antibacterial proteins BD-2, S100A8, S100A9, Muc1 and RegIIIa in HT-29 cells, which have essential roles in preventing bacterial infection. 20 Both Muc1 and RegIIIa are well-studied antibacterial proteins in the field of IL-22, which were also largely up-regulated by rhIL-22 as described above. The bactericidal activity of RegIIIa against Gram-positive bacteria is mediated by the formation of a hexameric membrane-permeabilizing pore on Gram-positive bacteria. 34 Of note, RegIIIc and RegIIIb, two other important molecules of the RegIII family in mouse, had a protective role against Gram-negative bacterial C. rodentium.
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Muc1 is a membrane-bound mucin and represents one of the major components of the intestinal mucus. 35 Its protective roles against ulcerative colitis and Crohn's disease have been demonstrated in mouse models as well. 36 Significantly, the up-regulation of Muc1 by rhIL-22 allows the intestinal mucosa to produce a completely firm inner mucus layer to prevent bacterial invasion. Third, rhIL-22 promotes the proliferation of HT-29, but does not affect cell apoptosis with or without serum starvation. These additional activities of IL-22 were crucial for maintaining the barrier function at the epithelial surface, especially in the case of epithelial damage driven by intestinal diseases. 6 The localization of the expression of IL-22 mRNA in rhesus macaque was also investigated in this study by real-time RT-PCR analysis. The results revealed that a relative higher expression level of IL-22 in immune tissues, and the highest expression was observed in the spleen. However, according to the mRNA expression data of normal human tissues from GTEx(GCID:GC12M068248), huIL-22 showed the highest expression in the lymph node among immune tissues, and the expression of huIL-22 in the spleen was even lower than other tissues (small intestine, lung and testis). Interestingly, IL-22 preferentially expressed in the tissues of the outer-body barrier, such as the lung, trachea and especially the intestinal system. The lowest expression was found in the duodenum when we further examined each part of the intestine. This result may be due to the lower presence of ILC3s in the duodenum, which is the main cellular source of IL-22 in the intestinal system. 5, 37 These findings suggest that IL-22 may play an important role in the gastrointestinal tract homeostasis of rhesus macaques.
In summary, we cloned the full-length cDNA of rhIL-22 from PHA-stimulated PBMCs and found that rhIL-22 was highly homologous to human IL-22 in sequence characteristics. Additionally, rhIL-22 showed similar mucosal epithelial associated bioactivities to that of human IL-22, such as activating the phosphorylation of STAT3 at Tyr705, inducing the production of anti-bacterial proteins and promoting the proliferation of HT-29 cells. Coincidently, rhIL-22 is preferentially expressed in the tissues of outer-body barriers, especially in intestinal system, apart from the liver, pancreas and immune tissues. Taken together, our results lead to the belief that rhesus macaques serve as therapeutic models for IL-22-associated intestinal diseases.
